Predictive Oncology Inc. (NASDAQ:POAI) Sees Large Increase in Short Interest

Predictive Oncology Inc. (NASDAQ:POAI) was the target of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 161,300 shares, a growth of 56.8% from the September 30th total of 102,900 shares. Approximately 2.5% of the company’s stock are sold short. Based on an average daily trading volume, of 2,710,000 shares, the short-interest ratio is presently 0.1 days.

Predictive Oncology Stock Performance

Shares of NASDAQ:POAI traded up $0.12 during midday trading on Friday, reaching $0.84. 276,799 shares of the company’s stock traded hands, compared to its average volume of 1,411,641. Predictive Oncology has a one year low of $0.55 and a one year high of $3.76. The stock has a 50 day moving average of $0.81 and a 200 day moving average of $1.14. The company has a market cap of $5.58 million, a price-to-earnings ratio of -0.25 and a beta of 1.13.

Predictive Oncology (NASDAQ:POAI) last announced its quarterly earnings results on Tuesday, August 13th. The medical instruments supplier reported ($0.68) earnings per share (EPS) for the quarter. Predictive Oncology had a negative net margin of 802.69% and a negative return on equity of 200.06%. The company had revenue of $0.28 million for the quarter. Sell-side analysts predict that Predictive Oncology will post -2.03 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright started coverage on shares of Predictive Oncology in a research report on Monday, August 19th. They set a “buy” rating and a $3.00 price target for the company.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.